Martha Morrell - Jan 30, 2024 Form 4 Insider Report for NeuroPace Inc (NPCE)

Signature
/s/ Irina Ridley, Attorney-In-Fact
Stock symbol
NPCE
Transactions as of
Jan 30, 2024
Transactions value $
-$208,965
Form type
4
Date filed
2/1/2024, 09:47 PM
Previous filing
Jan 26, 2024
Next filing
Feb 6, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NPCE Common Stock Sale -$170K -11.3K -10.31% $15.10 97.9K Jan 30, 2024 Direct F1, F2
transaction NPCE Common Stock Sale -$29K -1.92K -1.96% $15.08 96K Jan 31, 2024 Direct F1, F3
transaction NPCE Common Stock Sale -$9.97K -663 -0.69% $15.04 95.4K Feb 1, 2024 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.165, inclusive. The reporting person undertakes to provide the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.125, inclusive. The reporting person undertakes to provide the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.08, inclusive. The reporting person undertakes to provide the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.